Cheshire experts link with Japanese pharma giant on ‘superbug’ drug development
A Cheshire medical site at the centre of fighting superbugs has forged new links to develop next generation treatments to tackle the problem.
The AMR Centre has today (July 22) announced a landmark agreement with the Japanese pharma company Shionogi to take forward its anti-virulence programme, COT-143.
The therapy is designed to help the body tackle Pseudomonas aeruginosa infections, a hard-to-treat drug-resistant pathogen recognised by the World Health Organisation as a critical threat to human health.
COT-143 is a novel hu... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...